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Abstract
Aim To summarize the evidence on diabetes risk scores for Latin American populations.
Methods A systematic review was conducted (CRD42019122306) looking for diagnostic and prognostic models for
type 2 diabetes mellitus among randomly selected adults in Latin America. Five databases (LILACS, Scopus, MEDLINE,
Embase and Global Health) were searched. type 2 diabetes mellitus was defined using at least one blood biomarker and
the reports needed to include information on the development and/or validation of a multivariable regression model.
Risk of bias was assessed using the PROBAST guidelines.
Results Of the 1500 reports identified, 11 were studied in detail and five were included in the qualitative analysis. Two
reports were from Mexico, two from Peru and one from Brazil. The number of diabetes cases varied from 48 to 207 in
the derivations models, and between 29 and 582 in the validation models. The most common predictors were age, waist
circumference and family history of diabetes, and only one study used oral glucose tolerance test as the outcome. The
discrimination performance across studies was ~ 70% (range: 66–72%) as per the area under the receiving-operator
curve, the highest metric was always the negative predictive value. Sensitivity was always higher than specificity.
Conclusion There is no evidence to support the use of one risk score throughout Latin America. The development,
validation and implementation of risk scores should be a research and public health priority in Latin America to improve
type 2 diabetes mellitus screening and prevention.
Diabet. Med. 00: 1–12 (2019)
Introduction
Type 2 diabetes mellitus is a leading cause of morbidity,
disability and mortality worldwide [1–3], disproportionally
affecting low- and middle-income countries in Latin America
[4]. In addition, type 2 diabetes mellitus imposes a heavy
financial burden on local healthcare systems [5]. Therefore,
the increasing number of newly detected type 2 diabetes
mellitus cases creates challenges for low- and middle-income
countries [6]. The United Nations/World Health Organiza-
tion have set several goals to reduce the burden of non-
communicable diseases, including a 0% increase in diabetes
[7]. For Latin America, in particular, the Pan American
Health Organization has issued policies and guidelines for
the control and prevention of diabetes [8]. Epidemiological
evidence along with the active participation of international
health organizations, support the relevance of identifying
pragmatic strategies to reduce type 2 diabetes mellitus
burden at the population level.
A pragmatic, although still challenging solution is the early
identification of people with type 2 diabetes or those at high
risk of developing type 2 diabetes so that non-pharmaco-
logical and pharmacological prevention strategies can be
initiated. Diagnostic and prognostic models such as risk
scores are convenient for this purpose and yet their use is
limited to the population for which they were developed,
hence internal and external validation before application in
new populations are recommended. Although there have
been previous efforts to synthesize available risk scores
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globally [9–12], even focusing on Latin American popula-
tions in the USA [13], scientific information on type 2
diabetes risk scores in Latin American countries has been
limited. Therefore, whether there are scientifically validated
type 2 diabetes mellitus risk scores for populations in Latin
America remains unknown.
We aimed to critically review the current scientific
evidence on developed diabetes risk scores for Latin Amer-
ican populations. In so doing, we provide a list of risk scores
that could be further studied in different Latin American
countries, used by practitioners in countries where the
models were developed, or integrated by guideline/policy-
makers in the current standard of practice for diabetes
screening at the population level. Emphasis is placed on tools
developed for the general population because of their ability
to be used in different communities, thus benefiting popula-
tions beyond those accessing the health system [14–16].
Methods
Protocol and registration
This review is a systematic and critical appraisal of the
scientific literature following PRISMA guidelines and regis-
tered at PROSPERO (CRD42019122306) [17]. The review
framework adheres to international recommendations for
systematic reviews of prediction models and followed the
CHARMS strategy [18,19].
Eligibility criteria
Eligibility criteria for studies following the CHARMS
checklist are given in Table 1. In brief, we searched both
diagnostic and prognostic models aiming to inform general
practitioners (GPs), clinicians, researchers and the general
population about their current type 2 diabetes status (i.e.
diagnostic) or future risk (i.e. prognostic). The studies could
present results for models with or without external valida-
tion. The target population was adults in Latin America with
no restrictions on age.
Information sources
Five search engines were used systematically: LILACS,
Scopus, MEDLINE, Embase and Global Health; the last
three through Ovid. The search was conducted on 15
January 2019 with no time or language restrictions. The
search terms used are given in Appendices S1–S3.
Study selection
Reports were selected if the study population included men
and women who were both from and living in any Latin
American country. Thus, studies including Latin American
populations outside Latin America or those including only
foreigners living in Latin America were excluded. To be
included in this review, the study participants had to be a
randomly selected sample of the general population. Studies
of convenience samples were excluded. Furthermore, studies
including a specific subsample of people (e.g. studies in obese
or hypertensive people) as well as hospital-based samples
were excluded. The outcome of interest was previously
undiagnosed type 2 diabetes mellitus, defined using at least
one biomarker such as fasting glucose, random glucose, oral
glucose tolerance test or HbA1c. Studies in which the
outcome was defined solely based on self-reported diagnosis
were excluded. Reports needed to present the development
and/or validation procedures of a multivariable model.
Thus, studies assessing the diagnostic or predictive power
of one variable or biomarker alone were excluded. In
addition, both cross-sectional and cohort studies were
included.
Data collection process
Results from the literature search were downloaded into
EndNote and duplicates were removed. All unique results
were uploaded to Rayyan [20], an online systematic review
tool, whereby titles and abstracts were independently
screened by two reviewers (pairwise combinations between
RMC-L, DJA-G, JRM) and disagreements were solved by
consensus or by a third party (AB-O). Before screening, all
reviewers underwent a standardization process. Reports
selected from the screening phase were studied in detail by
What’s new?
• Risk scores are tools that could support screening,
diagnosis and prognosis decisions in clinical medicine
and public health.
• Risk scores for undiagnosed diabetes or to predict
diabetes are available worldwide with a few in Latin
America. However, the characteristics of risk scores
available for Latin America, their performance, pitfalls
and other attributes have not been summarized or
appraised.
• A lack of synthesized information makes it difficult to
understand the strengths and limitations of the avail-
able tools, hampering their implementation in clinical
and screening guidelines.
• We conducted a thorough search for risk scores for type
2 diabetes developed in Latin America, providing the
clinical and public health communities with evidence to
inform their decisions regarding these risk scores.
• Local and regional health organizations could recom-
mend one risk score or foster the development of a
stronger tool to overcome the limitations signalled
herein.
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two reviewers independently (RMC-L, DJA-G, JRM), and
disagreements were solved by consensus or by a third party
(AB-O). These processes led to the selection of reports for
inclusion in the qualitative summary, from which key
information was extracted onto a data collection form
developed by the authors based on international guidelines
for systematic reviews of prognosis models (CHARMS
checklist) [18,19]. The data collection form was not modified
afterwards. Information was extracted by one reviewer
(RMC-L) and independently verified by another (AB-O);
disagreements were solved by consensus.
Risk of bias of individual studies
Risk of bias was assessed following the PROBAST recom-
mendations, a risk of bias assessment tool developed exclu-
sively for prognosis models [21,22]. This process was
conducted by two reviewers independently (DJA-G and
JRM) and verified by a third (AB-O).
Synthesis of results
Only a qualitative synthesis was conducted. A quantitative
synthesis was not possible because of the small number of
reports using the same variables in the prediction models.
This study was classified as low risk because no human
participants were studied. This is a systematic review of the
scientific literature, which is public and can be accessed
freely.
Results
The initial search yielded 1546 results; 1500 titles and
abstracts were screened and 11 reports were studied in full.
Five reports were included in the qualitative synthesis (Fig. 1)
[23–27].
What has been done?
In 2018, Bernabe-Ortiz and colleagues derived a simplified
version of the FINDRISC, and validated the original
FINDRISC, the Latin America-FINDRISC and the Peruvian
Risk Score, i.e. they provided estimates for four models (one
derivation and three validations) [23]. In 2016, Bernabe-
Ortiz et al. derived a diagnostic model, which was validated
externally, using both cross-sectional and prospective data,
i.e. they provided estimates for three models (one derivation
and two validations) [24]. In 2018, Felix-Martinez and
Godınez-Fernandez derived and validated two models using
cross-sectional data collected in 2006 and 2012, i.e. they
provided estimates for four models (two derivations and
two validations) [25]. In 2010, Guerrero-Romero and
Rodrıguez-Moran derived a model using cross-sectional
data and validated it in prospective data, i.e. provided
estimates for two models (one derivation and one valida-
tion) [26]. Finally, in 2009, Pires de Sousa and colleagues
derived and validated a diagnostic model, i.e. they provided
estimates for two models (one derivation and one valida-
tion) [27]. Overall, six models were derived and nine
underwent validation analysis.
General characteristics
Two of the five reports studied people in Peru [23,24], two
studied Mexicans [25,26], and one was conducted in Brazil
[27]. The oldest analysed data was collected in 1996 [26],
and the remainder of the studies used data collected after
2000 [23–25,27]. The mean age of the participants in the
derivation models ranged from 42 to 50 years, and the
proportion of men varied from 38% to 51% [23–27]. The
mean age of people analysed in the validation models ranged
from 40 to 55 years, and the proportion of men ranged from
25% to 49% (Appendix S4) [23–27].
Table 1 Criteria to guide the literature search and selection criteria
Concept Criteria
Prognostic or diagnostic? Both, this review focuses on diagnostic and prognostic risk scores for type 2 diabetes mellitus
Scope Diagnostic/prognostic models to inform physicians, researchers and general population about their
current type 2 diabetes mellitus status (i.e. diagnostic) or risk of type 2 diabetes mellitus in the
future (i.e. prognostic)
Type of prediction modelling
studies
Focus on the three types: (i) diagnostic/prognostic models with external validation,
(ii) diagnostic/prognostic models without external validation, and (iii) diagnostic/prognostic models
validation
Target population to whom
the prediction model applies
General adult population in Latin America and the Caribbean; no age or gender restrictions
Outcome to be predicted type 2 diabetes mellitus (diagnostic or prognostic)
Time span of prediction Any; prognostic models will not be included/excluded based on the prediction time span
Intended moment of using the
model
Diagnostic/prediction models to be used in asymptomatic adults in Latin America to ascertain
current type 2 diabetes mellitus status (i.e. diagnostic) or future risk of type 2 diabetes mellitus
(i.e. prognostic); these models could be used for research purposes, screening and treatment allocation in
primary prevention
Based on the CHARMS checklist. [19]
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The sample size analysed to derive the diagnostic models
ranged from 711 [26] to 6995 people [25], and from 438 [26]
to 28 913 [25] for the validation models. The number of
diabetes cases varied greatly in the derivation models, from
48 [24] to 207 [25], with only two derivations models having
≥ 100 events; the equivalent numbers in the validation
models were 29 [27] and 582 [25], with two derivation
models having ≥ 100 events. Of note, this information
(number of outcome events or diabetes cases) could not be
extracted from Guerrero-Romero and Rodrıguez-Moran
[26]. The ratio of outcome events per number of candidate
predictors in the derivation analyses ranged from 3.43 [24] to
15.92 [25]. Across all reports, missing data were handled by
conducting a complete-case analysis [23–25,27], although
this information was not available in Guerrero-Romero and
Rodrıguez-Moran’s study [26] (Appendix S4)
All derivations models used a logistic regression analysis
[23–27]. In all but one report [26], it was clear that
preselection of predictors was conducted (i.e. choosing the
final list of predictors based on statistical significance),
mostly following a stepwise backward selection approach
(Appendix S4) [23–25,27]. In Felix-Martinez and Godınez-
Fernandez’s work, numerical variables were not categorized
[25], but this approach was followed in the other studies
FIGURE 1 Flowchart of the study selection process.
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[23,24,26,27]. As shown in Fig. 2, the most common
predictors used in the models were: age, waist circumference
and family history of diabetes (Appendix S4) [23–27].
Outcome ascertainment
Across reports, the outcome was new type 2 diabetes cases
based on standard laboratory procedures. It was not possible
to extract the definition used to diagnose new diabetes cases
from Guerrero-Romero and Rodrıguez-Moran’s work [26].
The other reports relied mostly on fasting plasma glucose
≥ 7.0 mmol/l (126 mg/dl) [23–25,27]. In addition to fasting
plasma glucose, Bernabe-Ortiz et al. also used 2-h plasma
glucose ≥ 11.1 mmol/l (≥ 200 mg/dl) [23]. Felix-Martinez
and Godınez-Fernandez [25] also defined new diabetes cases
according to random glucose ≥ 11.1 mmol/l (≥ 200 mg/dl)
(Appendix S4).
Model performance
Figure 3 shows the performance metrics for each derivation
model as presented in the original reports (Appendix S4) [23–
27]. Discrimination performance across studies was ~ 70%
as per the area under the receiving-operator curve, ranging
from 66% [25] to 72% [24,27]. Where reported, the negative
predictive value was the best metric, achieving almost 100%
[23,24,27]. Sensitivity was always larger than specificity [23–
25,27] and the largest absolute difference was 39.2%
(sensitivity, 85.9%; specificity, 46.7%) [23].
Figure 4 shows the performance metrics for the validation
models as reported originally (Appendix S4) [23–27].
Discrimination performance ranged from 64.0% [25] to
91.0% [26]. The best performance metric was the negative
predictive value, and sensitivity was always larger than
specificity (Appendix S4) [23–27]. In both prediction and
validation analyses, calibration metrics or plots were not
presented, though Bernabe-Ortiz et al. reported the Hosmer–
Lemeshow P-value (0.21) [24].
Risk of bias
Table 2 summarizes the risk of bias ascertainment, and full
details are provided in Appendix S5. Across all reports, the
participants’ criterion in the risk of bias assessment revealed
a low risk of bias; by contrast, the analysis criterion showed
high risk of bias mostly because of few numbers of outcome
events (i.e. diabetes cases) and conducting complete-cases
analysis instead of performing imputation methods. Across
summarized studies, there was a low concern regarding
applicability as models were created from population-based
studies.
Discussion
Main findings
This systematic review of the literature synthesized the
available risk scores for type 2 diabetes mellitus that can be
used in Latin American general populations and countries,
providing evidence and tools for practitioners as well as
guideline/policy-makers across Latin America. Five reports
from three countries (Brazil, Mexico and Peru) were
summarized [23–27], which developed five diagnostic tools;
two of them also conducted a longitudinal assessment
[24,26]. In addition, these five reports provided results for
the validation of nine models [23–27]. Although discrimina-
tion estimates were largely acceptable, calibration metrics
were not reported. The negative predictive value was the
highest metric across risk scores [23–27]. Even though
several type 2 diabetes mellitus risk scores have been
developed for Latin American populations, few have fol-
lowed optimal analytical approaches regarding internal and
FIGURE 2 Predictors included in the final diagnosis and prognosis models. The colours of the bars identify the underlying characteristic of predictors
inherent to: the subject (black), anthropometrics (orange), clinical assessment and history (blue) and lifestyle-related behaviours (purple).
ª 2019 The Authors.
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external validation. For countries (Brazil, Mexico and Peru)
where risk scores were generated and validated both cross-
sectionally and prospectively, there is enough scientific
evidence to implement them as part of the standard of care
for type 2 diabetes mellitus screening at the population level.
Limitations of the review
This is a sound methodological review following interna-
tional guidelines for the systematic reviews of prognosis
models [18,19,21,22]. In addition, we used several search
engines including ones based in Latin America, hence most, if
not all, available evidence should have been retrieved.
However, we did not systematically search grey literature,
e.g. dissertations. We argue that this potential limitation
would not change our overall findings and conclusions,
because these sources would usually not retrieve population-
based studies and would have the same or more method-
ological issues.
Limitations of the selected reports
Most of the reports ascertained the outcome based on fasting
glucose, yet one effort in Peru also used oral glucose
tolerance test [23].
It could be argued that results based on fasting glucose, or
any single biomarker, could lead to underestimation, i.e.
some cases might have not been detected. Nonetheless, we
FIGURE 3 Performance metrics of the derivation models. Guerrero-Romero and Rodrıguez-Moran [26] did not provide these details for the
derivation models, thus it was left blank. Pires de Sousa et al. [27] presented these metrics for several thresholds (Appendix S4), the ones shown here
correspond to the cut-off point with sensitivity closest to the pre-specified value. Bernabe-Ortiz et al. [24] presented these metrics for several
thresholds (Appendix S4), the ones shown here correspond to those with the best Youden Index. A, Pires de Souza, 2009; B, Bernabe-Ortiz, 2016; C,
Bernabe-Ortiz, 2018; D, Felix-Martinez, 2018 (2006 data); E, Felix-Martinez, 2018 (2012 data); F, Guerrero-Romero, 2010. NPV, negative
predictive value; PPV, positive predictive value.
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need to acknowledge that these studies were conducted in
low- and middle-income countries, sometimes in rural areas,
were laboratory facilities to analyse a wider range of
biomarkers is limited. In any case, this limitation does not
invalidate the results, but rather invites additional investiga-
tions to further confirm them using more/other biomarkers.
Furthermore, most of the selected reports followed a cross-
sectional design, which is not suitable for assessing prognos-
tic models (i.e. long-term outcomes). In addition, the study
populations were rather young, which further limits the
implementation of the available tools in very young individ-
uals (e.g. adolescent or early adulthood) as well as among the
elderly.
There were three main methodological limitations: (i)
continuous predictors were categorized, (ii) there was prese-
lection of the predictors, and (iii) some studies included a
limited number of diabetes cases. The first two limitations
have been identified as common but suboptimal approaches
that hamper the prediction accuracy of the models [28]. Some
authors may argue that categorizing continuous predictors
helps to make the risk score friendlier thus fostering their use.
Whether this argument supersedes the statistical limitations
remains unknown.Nevertheless, there are other ways tomake
the risk scores more accessible such as the use of mobile apps
that could include a ‘complex’ algorithm without compro-
mising statistical power. Alternatively, a spreadsheet could
accompany the main report as supplementary material, also
containing a ‘complex’ algorithm ready to be used. Preselec-
tion of predictors was a common practice, following a
backward elimination technique [23–25,27]. This could lead
to the omission of important predictors that by chance, are not
statistically associated with the outcome in the training data
FIGURE 4 Performance metrics of the validation models. Pires de Sousa et al. [27] presented these metrics for several thresholds (Appendix S4), the
ones shown here correspond to the cut-off point with the sensitivity closest to the pre-specified value. Bernabe-Ortiz et al. [24] presented these
metrics for several thresholds (Appendix S4), the ones shown here correspond to those with the best Youden Index. A, Pires de Souza, 2009; B,
Bernabe-Ortiz, 2016 (cross-sectional); C, Bernabe-Ortiz, 2016 (longitudinal); D, Bernabe-Ortiz, 2018 (FINDRISC); E, Bernabe-Ortiz, 2018 (LA-
FINDRISC); F Bernabe-Ortiz, 2018 (Peruvian); G, Felix-Martinez, 2018 (2006 data); H, Felix-Martinez, 2018 (2012 data); I, Guerrero-Romero,
2010. NPV, negative predictive value; PPV, positive predictive value.
ª 2019 The Authors.
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set; moreover, this could lead to over-fitting the risk model
[29]. A general recommendation could be to conduct a
systematic review of available models in the field to identify
the most common and relevant predictors; alternatively,
expert knowledge should be included rather than statistical
significance alone. Our work could help to overcome this
limitation for future studies. We have summarized the most
common predictors, so that future efforts could select these
instead of ‘sampling’ within a pool of variables available in the
data. The number of predictors was small in some derivation
models; most importantly, this was also the case in the
validation models. It has been suggested that for external
validation, at least 100 events should be available [30]. An
additional methodological limitation, although one that has
little impact in the selected studies, was analysing a complete-
case data set, i.e. not conducting methods to account for the
missing observations. Multiple imputation techniques still
seem to be conducted poorly or not be particularly popular
among Latin American health data analysis.
Several metrics for the performance of the risk scores
were reported, although calibration estimates were not
available. Calibration is important because it tells us
whether the prediction computed by the model agrees
with what is actually observed; in other words, a poor
calibration could result in overestimation (when the model
predicts higher risk than the actual observed risk) or
underestimation (when the model predicts lower risk than
the actual observed risk) [29,31]. Although Bernabe-Ortiz
and colleagues reported the Hosmer–Lemeshow P-value
[24], further details such as a calibration plot comparing
observed vs. predicted cases were missing. The absence of
this performance metric but the presentation of other
clinically relevant metrics such as sensitivity, specificity and
negative/positive predictive values, highlight a need for
further training in diagnostic/prediction models analysis.
Regarding negative/predictive values, it is relevant to signal
that these depend on the underlying prevalence in the
population; therefore, these metrics should be interpreted
in line with the prevalence estimates and would not be
useful to compare prediction models across countries with
very different prevalence rates. Given the relevance that
risk scores may have in clinical medicine and public health,
Table 2 Risk of bias assessment of individual diagnostic/prognostic models (PROBAST)
Study; first
author, date Objective
Risk of bias Applicability Overall
Participants Predictors Outcome Analysis Participants Predictors Outcome
Risk
of
bias applicability
Pires de Sousa,
2009 [27]
Derivation + + +  + + + ? +
Pires de Sousa,
2009 [27]
Validation + + +  + + + ? +
Bernabe-Ortiz,
2016 [27]
Derivation + + +  + + + ? +
Bernabe-Ortiz,
2016 [27]
Validation + + +  + + + ? +
Bernabe-Ortiz, 2018
(FINDRISC) [23]
Validation + + +  + + +  +
Bernabe-Ortiz, 2018
(Latin America-
FINDRISC) [23]
Validation + + +  + + +  +
Bernabe-Ortiz, 2018
(Peruvian) [23]
Validation + + +  + + +  +
Bernabe-Ortiz, 2018
(Simplified
FINDRISC) [23]
Derivation + + +  + + +  +
Felix-Martinez, 2018
(NHNS-2006) [25]
Derivation + ? ?  + + +  +
Felix-Martinez, 2018
(NHNS-2012) [25]
Derivation + ? ?  + + +  +
Felix-Martinez, 2018
(NHNS-2006) [25]
Validation + ? ?  + + +  +
Felix-Martinez, 2018
(NHNS-2012) [25]
Validation + ? ?  + + +  +
Guerrero-Romero,
2010 [26]
Derivation ?    ? -   
Guerrero-Romero,
2010 [26]
Validation +    +    
PROBAST, Prediction model Risk of Bias ASsessment Tool [21,22]; +, low risk of bias/low concern regarding applicability; , high risk of
bias/high concern regarding applicability; ?, unclear risk of bias/unclear concern regarding applicability.
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strengthening the analytical skills in this field appears to be
necessary. Even though friendly technical literature is
available [29,32–36], the equivalent in Spanish, the
language mostly spoken throughout Latin America, is
limited.
Because the Transparent Reporting of a multivariable
prediction model for Individual Prognosis or Diagnosis
(TRIPOD) statement was published in 2015 [37,38], studies
published before that date could not have adhered to this
reporting checklist. Studies published after, by contrast,
could have adhered to TRIPOD but probably did not because
they were unaware of it, suggesting a lack of experience in
the field and poor penetration of this statement across
professions and regions. Another limitation regarding pre-
sentation of the results was the fact that only one study
reported the baseline risk, i.e. the intercept of the logistic
regression [25]. This parameter is not generally reported and
can make it difficult for other researchers to recalibrate these
tools for other populations or countries.
Overall, the synthesized prediction models exhibited some
methodological limitations. Although these do not invalidate
the results, they further support the need to improve this
research area in Latin America, for diabetes and other
conditions, including several non-communicable diseases.
Conducting sound and methodologically robust analyses is
key to taking advantage of all the available data and produce
better tools that could be easily scaled to clinical medicine
and supported by guidelines or policies.
Additional evidence
This review focused on population-based studies with
random sampling, although this does not mean that studies
following different sampling methods are of little relevance.
To develop risk scores, random samples of the general
population are not essential. Reports with different sampling
criteria have provided valuable information and pragmatic
tools for Latin American countries, and thus deserve to be
acknowledged as well.
In Mexico, Rojas-Martinez et al. using data of a cohort of
public and private servants developed a risk score for
undiagnosed diabetes; although the external validation was
conducted on a population-based sample, this endeavour was
not selected for the main synthesis because the model was
generated in a closed population [39]. Their score yielded a
discrimination of 60% in men and 63% in women, speci-
ficity was larger than sensitivity, and the negative predictive
value was the largest metric [39]. In addition, the authors
compared this new tool with the one currently recommended
in Mexico, concluding that the new one performed better
[39]. This work signalled that additional research on
prediction models benefiting of new and larger data could
be useful to improve and update current guidelines.
In Colombia, Barengo and colleagues analysed data of an
insurance company to develop a risk score for undiagnosed
type 2 diabetes mellitus [40]. Their model had a discrimina-
tion of 74%, slightly higher than the internationally known
FINDRISC (73%) [40]. However, this study was not tested
externally [40], leaving room for further validation in the
general population. Other Colombian researchers have also
tested the accuracy of the FINDRISC score, this time using
data for people at a primary care facility [41]. They reported
a discrimination of 72% in women and 75% in men for
undiagnosed type 2 diabetes mellitus [41]; these numbers for
incident diabetes were 68% in women and 72% in men [41].
Although these two Colombian experiences should undergo
further validation, they signal that available risk scores have
a relevant prediction accuracy that could provide valuable
tools to improve the early diagnosis of type 2 diabetes
mellitus in Colombia.
A recent study in Venezuela also tested the Latin American
version of the FINDRISC score, concluding that people
above the proposed threshold must have an additional
diagnostic test, e.g. oral glucose tolerance test [42]. Because
Munoz-Gonzalez et al. studied volunteers attending car-
diometabolic screening campaigns, further validation is
warranted with a larger and more heterogenous study
population.
Central America has contributed poorly to this systematic
review, which calls researchers and health officers from this
region to conduct studies to develop efficient approaches to
early identify people with type 2 diabetes mellitus. However,
Milton and collaborators developed a prognostic model
benefiting from data of a primary care clinic; their model
yielded a discrimination of 89% [43]. Despite the limitations
of this work, it is worth acknowledging that the model was
intended for rural populations in Honduras, who have been
underrepresented to date in the selected and discussed type 2
diabetes mellitus risk scores.
Clinical and public health relevance
Clinical guidelines provide recommendations for type 2
diabetes mellitus screening. The Latin American guidelines,
issued by the Latin America Diabetes Association (Asocia-
cion Latinoamericana de Diabetes), recommends screening
with fasting glucose if a person has one of more risk factors
(e.g. overweight, abdominal obesity, family history of type 2
diabetes mellitus) [44]. In addition, if a person is ≥ 45 years
old, they should be screened with a fasting glucose test at
least once every 5 years, although this could be more often
depending on the co-existence of other risk factors [44]. Of
note, this guideline also recommends the use of a validated
risk score such as the FINDRISC, which could guide the
decision on whether or not someone should be screened using
fasting glucose [44]. However, about one third of people
with undetected type 2 diabetes have normal fasting glucose
levels but 2-h postprandial glucose values of > 200 mg/dl.
Our work provides evidence on additional type 2 diabetes
mellitus risk scores locally developed and validated in Latin
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America, thereby this and other guidelines can update their
recommendations with strong regional evidence to secure
better and more reliable diabetes screening in Latin American
populations.
American guidelines also propose screening individuals
with risk factors, and suggest using the American Diabetes
Association risk test to inform the decision on who should
undergo further diagnostic tests (e.g. fasting glucose) [45].
Similarly, the Canadian guidelines propose screening people
based on risk factors, or using the Canadian Diabetes Risk
Assessment Questionnaire (CANRISK) [46]. Importantly,
both, the American and Canadian guidelines, include locally
developed and validated risk scores. Furthermore, the Cana-
dian guidelines offer a brief but solid preface on the relevance
of using validated risk scores [46]. By contrast, the Latin
American guidelines simply suggest use of a ‘validated risk
score’. Apparently, this general recommendation was made
in the absence of a comprehensive list of available type 2
diabetes mellitus risk scores for Latin American populations.
Thus, our systematic review fills this knowledge gap provid-
ing scientific evidence to improve regional- and country-
based guidelines for the detection of type 2 diabetes mellitus.
It may seem bold to seek one risk score for Latin America
as a region, but still worth trying because it could bring great
benefits in population screening and disease prevention. With
relevant methods, as shown in cardiovascular medicine
[47,48], along with support from stakeholders and profes-
sional bodies, one or a series of country-specific risk scores
could be acceptable and strongly recommended throughout
Latin America.
Conclusions
This systematic review of risk scores for the diagnosis and
prognosis of type 2 diabetes mellitus could not find
compelling evidence to strongly support the use of one single
diabetes risk score throughout Latin America. Conversely,
there was good evidence to support the use of validated risk
scores in Peru and Mexico, whereas further studies need to
be conducted with a multi-country or regional scope.
Because risk scores could provide additional options to
identify type 2 diabetes mellitus cases early, hence decreasing
the burden of this disease, the development, validation and
implementation of accurate risk scores should be a research
and public health priority in Latin America and other low-
and middle-income regions.
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